ArticleScientific reports2025
A nomogram using transition zone PSA density for detecting clinically significant prostate cancer in PI-RADS 3 lesions.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Value of PSA density in PI-RADS 3 lesions: a single-center retrospective observational study.International urology and nephrology · 2026Observational
- Comprehensive biochemical insights into derivatives of PSA and glycosylation-specific changes in PSA: role in diagnosis and management of prostate cancer.Clinical proteomics · 2026Review
- Navigating PI-RADS v2.1 in clinical practice: pitfalls, variability, and the supportive role of AI.Abdominal radiology (New York) · 2026Review
- Beyond Total PSA: Clinical Significance of S2,3PSA% in Reducing Unnecessary Prostate Biopsies.International journal of urology : official journal of the Japanese Urological Association · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to explore several transitional zonal (TZ)-adjusted parameters for the prediction of clinically significant prostate cancer (csPCa) that categorized as Prostate Imaging Reporting and Data System (PI-RADS) score 3 lesions. A total of 288 patients who underwent multiparametric MRI (mpMRI) and MRI/US targeted fusion biopsy between January 2017 and March 2024 were included in this retrospective study, which was randomly assigned as training dataset and validation dataset. Diagnostic performance of different variables was analyzed using receiver operating characteristics (ROC) and compared with area under ROC (AUC). Univariable and multivariable logistic regression analysis were used to determine significant variables, and a nomogram integrating these parameters was developed. The calculated AUC for prostate-specific antigen density (PSAD), TZ volume (TZV), PSAD based on TZ (TZ-PSAD), and TZ volume ratio (TZ-ratio) were 0.644 (95% CI 0.558–0.731), 0.710 (95% CI 0.610–0.810), 0.724 (95% CI 0.638–0.809), and 0.735 (95% CI 0.650–0.820), respectively. The Delong test demonstrated that TZ-PSAD and TZ-ratio outperformed PSAD, with P = 0.002 and P = 0.04. AUC for model integrating age, TZ-PSAD, and TZ-ratio was 0.834 (95% CI 0.764–0.904), which outperformed TZ-PSAD (P = 0.003) and TZ-ratio (P = 0.007) alone. Zonal-adjusted variables showed promising diagnostic accuracy for the detection of csPCa among lesions scored as PI-RADS category 3, and both TZ-PSAD and TZ-ratio outperformed the whole gland PSAD. Moreover, the model incorporating age, TZ-PSAD, and TZ-ratio could further improve the overall diagnostic performance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.